Table 2.

Adjusted landmark analysis of the association of MR-proADM with day-60 mortality on days 1, 3, and 7.

	Hazard Ratio	95% Confidence Interval	p
Landmark at day 1 (n = 135)
Day-1 MR-proADM	1.17	(1.06–1.28)	<0.01
Day-1 CRP	1.00	(1–1)	0.50
Day-1 lymphocytes count	1.00	(1–1)	0.28
Day-1 LDH	1.00	(1–1)	<0.01
Landmark at day 3 (n = 135)
Day-3 MR-proADM	1.17	(1.06–1.28)	<0.01
Day-1 CRP	1.00	(0.99–1)	0.50
Day-1 lymphocytes count	1.00	(1–1)	0.28
Day-1 LDH	1.00	(1–1)	<0.01
Landmark at day 7 (n = 128)
Day-7 MR-proADM	1.19	(1.1–1.31)	<0.01
Day-1 CRP	1.00	(0.99–1)	0.65
Day-1 lymphocytes count	1.00	(1–1)	0.62
Day-1 LDH	1.00	(1–1)	<0.01

Missing data imputed by multiple imputation. Hazard ratios are computed per one point of each variable. Abbreviations: MR-proADM, Mid-regional proadrenomedullin; CRP, C-reactive protein; LDH, Lactate Dehydrogenase.